If you have $200 to spend on health in a developing country, would you vaccinate 10 children against deadly childhood diseases or provide AIDS treatment to one woman to prevent transmission of HIV to her unborn child? Policy makers routinely face such tough budgetary dilemmas with little expert guidance. The working group is investigating practical means to assist priority-setting efforts in low- and middle-income countries.
Global health initiatives call for greater developing country financing of cost-effective health interventions for an increasingly diverse set of disease control priorities. But while the priorities are many and population demands increase alongside growing educational attainment and technological innovation, public funding–even when augmented by donor contributions or technology price reductions–remains scarce, and difficult decisions must be made.
There are clear health gains to be made from shifting the current distribution of public spending to more cost-effective uses. For example, WHO estimates that reallocating malaria control budgets in Zambia towards a more cost-effective mix of interventions could reduce costs per Disability Adjusted Life Year (DALY) gained by up to 20%. In Thailand, there is room for as much as a 99% improvement in health impact by reallocating spending for cardiovascular disease prevention. Overall, the WHO estimates that low income countries could save as much as 12-24% of total health care spending.
There is also a growing global knowledge base of data, methods and tools to support countries in the adoption and implementation of cost-effectiveness analyses and health technology assessments, as well as a rich literature on the importance of process itself in constructing ethical, transparent and durable public spending decisions in the health sector.
Yet most public spending decisions do not explicitly incorporate evidence or process, even while global health agencies and donors are expecting recipient governments to assume more and more of the expenses of cost-effective interventions over time. The lack of an explicit process also poses an ethical and a practical problem for donors; as when, for example, PEPFAR funds are available to treat only 30% of HIV-positive adults and no formal process is in place to help recipients make the terrible decisions on who receives treatment and who goes without.
The working group on Priority-Setting Institutions for Global Health is identifying the characteristics of processes and institutions that are capable of transparently and ethically translating scientific and economic evidence and social preferences on health technologies into on-budget priorities in low- and middle-income settings. In addition, the group will assess current and potential international support for priority-setting institutions, recognizing that while public funding decisions are necessarily driven by local structures and values, shared regional or global information bases for decision-making, institutional design, technical accompaniment and peer support would add much needed value and support to traditionally opaque methods of resource allocation.
Priority setting institutions for health working group member, Dr. Lydia Kapiriri, speaks here about her research within a Ugandan hospital and how her findings can be used to improve priority setting practices in developing nations.
Working Group Members
The Working Group brings together a multi-disciplinary group of policy-makers, practitioners, experts and academics from industry, regulatory authorities, donor agencies, technical agencies and universities. Members serve in a personal capacity, independent of their institutional affiliation.
Kalipso Chalkidou (co-chair), National Institute for Health and Clinical Excellence, UK
Amanda Glassman (co-chair), Center for Global Development, USA
Sara Bennett, John Hopkins School of Public Health, USA
Adriana Velazquez Berumen, World Health Organization
Tomasz Bochenek, Jagellonian University, Poland
Michael Borowitz, Organization for Economic Co-operation and Development
Jesse Bump, Georgetown University, USA
Leonardo Cubillos, World Bank Institute
Tessa Edejer, World Health Organization
Ruth Faden, Johns Hopkins Berman Institute of Bioethics
Jeremy Farrar, Oxford University Clinical Research Unit, Vietnam
Armin Fidler, The World Bank
James Fitzgerald, Pan American Health Organization
Ursula Giedion, Independent, Colombia
Charles Hongoro, South African Medical Research Council, South Africa
Dai Hozumi, PATH, USA
Lydia Kapiriri, McMaster University, Canada/Uganda
Felicia Knaul, Harvard University, USA/Mexico
Zhao Kun, China Health Economics Institute, China
Rachel Nugent, Disease Control Priorities Network, University of Washington, USA
Andres Pichon-Riviere, Instituto de Efectividad Clinica y Sanitaria, Argentina
Diana Pinto, Inter-American Development Bank, USA
Mala Rao, Indian Institute of Public Health, Hyderabad, India
Michael Rawlins, National Institute for Health and Clinical Excellence, UK
Alarico Rodriguez, The National Resources Fund, Uruguay
Lloyd Sansom, University of South Australia, Australia
Jeremy Shiffman, American University, USA
Yot Teerawattananon, Health Intervention and Technology Assessment Program, Thailand
Ignez Tristao, Inter-American Development Bank, Brazil
Sean Tunis, Center for Medical Technology Policy, USA
Damian Walker, The Bill & Melinda Gates Foundation, USA
Photo by Flickr user hdptcar